ATE355076T1 - Zusammensetzungen und methoden zur systemischen verabreichung von oralen impfstoffen und therapeutischen wirkstoffen - Google Patents
Zusammensetzungen und methoden zur systemischen verabreichung von oralen impfstoffen und therapeutischen wirkstoffenInfo
- Publication number
- ATE355076T1 ATE355076T1 AT98953617T AT98953617T ATE355076T1 AT E355076 T1 ATE355076 T1 AT E355076T1 AT 98953617 T AT98953617 T AT 98953617T AT 98953617 T AT98953617 T AT 98953617T AT E355076 T1 ATE355076 T1 AT E355076T1
- Authority
- AT
- Austria
- Prior art keywords
- compositions
- methods
- active ingredients
- systemic administration
- therapeutic active
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 title 1
- 229940126578 oral vaccine Drugs 0.000 title 1
- 238000007910 systemic administration Methods 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 108030001720 Bontoxilysin Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 229940053031 botulinum toxin Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/954,302 US6051239A (en) | 1997-10-20 | 1997-10-20 | Compositions and methods for systemic delivery of oral vaccines and therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE355076T1 true ATE355076T1 (de) | 2006-03-15 |
Family
ID=25495232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98953617T ATE355076T1 (de) | 1997-10-20 | 1998-10-16 | Zusammensetzungen und methoden zur systemischen verabreichung von oralen impfstoffen und therapeutischen wirkstoffen |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6051239A (de) |
| EP (1) | EP1024827B1 (de) |
| JP (1) | JP2001522783A (de) |
| KR (1) | KR100594787B1 (de) |
| CN (1) | CN1246038C (de) |
| AT (1) | ATE355076T1 (de) |
| AU (1) | AU756475B2 (de) |
| BR (1) | BR9815255A (de) |
| CA (1) | CA2306995A1 (de) |
| DE (1) | DE69837209T2 (de) |
| EE (1) | EE200000536A (de) |
| HU (1) | HUP0101017A3 (de) |
| IL (1) | IL135743A (de) |
| NZ (1) | NZ504549A (de) |
| RU (1) | RU2227042C2 (de) |
| WO (1) | WO1999020306A1 (de) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7227010B2 (en) | 1993-09-21 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Army | Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy |
| US6967088B1 (en) * | 1995-03-16 | 2005-11-22 | Allergan, Inc. | Soluble recombinant botulinum toxin proteins |
| US20030118598A1 (en) * | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
| US8632785B2 (en) * | 2000-02-08 | 2014-01-21 | Allergan, Inc. | Clostridial toxin pharmaceutical composition containing a gelatin fragment |
| ES2237551T3 (es) * | 2000-02-08 | 2005-08-01 | Allergan, Inc. | Composiciones farmaceuticas que contienen toxina botulinica. |
| US7780967B2 (en) * | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
| US20060269575A1 (en) * | 2000-02-08 | 2006-11-30 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions formulated with recombinant albumin |
| US6903187B1 (en) * | 2000-07-21 | 2005-06-07 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
| DE60130266D1 (de) * | 2000-11-06 | 2007-10-11 | Us Army Med Res Mat Command | Rekombinante leichte kette des botolinum neurotoxins and fusionsproteine davon zur verwendung in forschung und klinischer therapie |
| US7273722B2 (en) * | 2000-11-29 | 2007-09-25 | Allergan, Inc. | Neurotoxins with enhanced target specificity |
| JP4707254B2 (ja) * | 2001-04-24 | 2011-06-22 | クミアイ化学工業株式会社 | 粒状組成物及びその製造方法 |
| US7691394B2 (en) * | 2002-05-28 | 2010-04-06 | Botulinum Toxin Research Associates, Inc. | High-potency botulinum toxin formulations |
| US20040013687A1 (en) * | 2002-05-31 | 2004-01-22 | Thomas Jefferson University | Compositions and methods for transepithelial molecular transport |
| US20040086532A1 (en) * | 2002-11-05 | 2004-05-06 | Allergan, Inc., | Botulinum toxin formulations for oral administration |
| EP1629090B1 (de) * | 2002-11-06 | 2014-03-05 | iBio, Inc. | Expression von fremdsequenzen in pflanzen unter verwendung eines trans-aktivierungssystems |
| US7683238B2 (en) * | 2002-11-12 | 2010-03-23 | iBio, Inc. and Fraunhofer USA, Inc. | Production of pharmaceutically active proteins in sprouted seedlings |
| US7692063B2 (en) * | 2002-11-12 | 2010-04-06 | Ibio, Inc. | Production of foreign nucleic acids and polypeptides in sprout systems |
| NZ540425A (en) * | 2002-12-20 | 2009-03-31 | Botulinum Toxin Res Ass Inc | Pharmaceutical botulinum toxin compositions |
| ES2531125T3 (es) | 2003-02-03 | 2015-03-10 | Ibio Inc | Sistema para la expresión de genes en plantas |
| US20040253274A1 (en) * | 2003-06-11 | 2004-12-16 | Allergan, Inc. | Use of a clostridial toxin to reduce appetite |
| US7172764B2 (en) * | 2003-11-17 | 2007-02-06 | Allergan, Inc. | Rescue agents for treating botulinum toxin intoxications |
| US20050129677A1 (en) * | 2003-12-10 | 2005-06-16 | Shengwen Li | Lipid rafts and clostridial toxins |
| ES2532609T3 (es) * | 2004-02-20 | 2015-03-30 | Ibio, Inc. | Sistemas y métodos para expresión clonales en plantas |
| US7306807B2 (en) | 2004-09-13 | 2007-12-11 | Wyeth | Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease |
| JP4994241B2 (ja) * | 2004-11-22 | 2012-08-08 | ニューヨーク・ユニバーシティ | 遺伝子操作されたクロストリジウム遺伝子、操作された遺伝子によりコードされるタンパク質、およびその使用 |
| WO2007042884A1 (en) | 2005-10-07 | 2007-04-19 | Pfizer Products Inc. | Vaccines and methods to treat canine influenza |
| DK1931379T3 (da) | 2005-10-07 | 2013-08-19 | Sec Dep For Health | Proteiner med forbedret opløselighed samt fremgangsmåder til frembringelse og anvendelse af samme |
| EP2155883A1 (de) * | 2007-05-30 | 2010-02-24 | Wyeth LLC | Gene aus felinen antigenen zur expression des waschbärpockenvirus |
| US8445650B2 (en) * | 2007-09-25 | 2013-05-21 | Thomas Jefferson University | Mutant botulinum neurotoxin serotype A polypeptide and uses thereof |
| CA2745657C (en) | 2008-12-04 | 2022-06-21 | Botulinum Toxin Research Associates, Inc. | Extended length botulinum toxin formulation for human or mammalian use |
| US9393291B2 (en) | 2012-04-12 | 2016-07-19 | Botulinum Toxin Research Associates, Inc. | Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds |
| WO2014117148A1 (en) | 2013-01-28 | 2014-07-31 | New York University | Treatment methods using atoxic neurotoxin derivatives |
| US9901627B2 (en) | 2014-07-18 | 2018-02-27 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
| US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
| US11897921B2 (en) | 2014-12-09 | 2024-02-13 | New York University | Propeptide fusion comprising a mutated clostridium botulinum neurotoxin and a VHH domain |
| WO2019126502A1 (en) | 2017-12-20 | 2019-06-27 | Allergan, Inc. | Botulinum toxin cell binding domain polypeptides and methods of use for skin rejuvenation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5919665A (en) * | 1989-10-31 | 1999-07-06 | Ophidian Pharmaceuticals, Inc. | Vaccine for clostridium botulinum neurotoxin |
| DE69511860T2 (de) * | 1994-05-31 | 2000-02-10 | Allergan, Inc. | Modifizierung von clostridium-toxinen und ihre anwendung als transport proteine |
| JP2002514886A (ja) * | 1994-10-24 | 2002-05-21 | プロメガ コーポレーション | クロストリジウム・ディフィシル疾患の治療及び予防のためのワクチン及び抗トキシン |
| WO1996040229A1 (en) * | 1995-06-07 | 1996-12-19 | Thomas Jefferson University | Vaccines synthesized by transgenic plants |
| WO1997032599A1 (en) * | 1996-03-08 | 1997-09-12 | The Regents Of The University Of California | Chemically-modified clostridiatoxin with improved properties |
-
1997
- 1997-10-20 US US08/954,302 patent/US6051239A/en not_active Expired - Fee Related
-
1998
- 1998-10-16 CA CA002306995A patent/CA2306995A1/en not_active Abandoned
- 1998-10-16 EE EEP200000536A patent/EE200000536A/xx unknown
- 1998-10-16 CN CNB988112981A patent/CN1246038C/zh not_active Expired - Fee Related
- 1998-10-16 IL IL13574398A patent/IL135743A/en not_active IP Right Cessation
- 1998-10-16 HU HU0101017A patent/HUP0101017A3/hu unknown
- 1998-10-16 NZ NZ504549A patent/NZ504549A/xx unknown
- 1998-10-16 BR BR9815255-6A patent/BR9815255A/pt not_active Application Discontinuation
- 1998-10-16 AT AT98953617T patent/ATE355076T1/de not_active IP Right Cessation
- 1998-10-16 DE DE69837209T patent/DE69837209T2/de not_active Expired - Fee Related
- 1998-10-16 RU RU2000112547/15A patent/RU2227042C2/ru not_active IP Right Cessation
- 1998-10-16 KR KR1020007004197A patent/KR100594787B1/ko not_active Expired - Fee Related
- 1998-10-16 EP EP98953617A patent/EP1024827B1/de not_active Expired - Lifetime
- 1998-10-16 AU AU10947/99A patent/AU756475B2/en not_active Ceased
- 1998-10-16 WO PCT/US1998/021897 patent/WO1999020306A1/en not_active Ceased
- 1998-10-16 JP JP2000516701A patent/JP2001522783A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1024827A1 (de) | 2000-08-09 |
| KR20010031236A (ko) | 2001-04-16 |
| JP2001522783A (ja) | 2001-11-20 |
| HUP0101017A3 (en) | 2003-11-28 |
| RU2227042C2 (ru) | 2004-04-20 |
| HUP0101017A2 (hu) | 2001-07-30 |
| CA2306995A1 (en) | 1999-04-29 |
| DE69837209D1 (de) | 2007-04-12 |
| WO1999020306A1 (en) | 1999-04-29 |
| KR100594787B1 (ko) | 2006-07-03 |
| BR9815255A (pt) | 2001-12-26 |
| EP1024827A4 (de) | 2002-08-28 |
| IL135743A (en) | 2004-03-28 |
| EE200000536A (et) | 2002-04-15 |
| US6051239A (en) | 2000-04-18 |
| AU756475B2 (en) | 2003-01-16 |
| AU1094799A (en) | 1999-05-10 |
| IL135743A0 (en) | 2001-05-20 |
| NZ504549A (en) | 2002-12-20 |
| CN1290174A (zh) | 2001-04-04 |
| CN1246038C (zh) | 2006-03-22 |
| DE69837209T2 (de) | 2007-10-31 |
| EP1024827B1 (de) | 2007-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1024827A4 (de) | Zusammensetzungen und methoden zur systemischen verabreichung von oralen impfstoffen und therapeutischen wirkstoffen | |
| ATE306931T1 (de) | Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer | |
| RU2000112547A (ru) | Композиции и способы системной доставки пероральных вакцин и терапевтических агентов | |
| BG103552A (bg) | Терапевтични средства | |
| NO971889D0 (no) | Forbindelser og sammensetninger for levering av aktive midler | |
| ATE435294T1 (de) | Verabreichung von biologisch aktiven polypeptiden | |
| NO20015584L (no) | Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling | |
| TR200002855T2 (tr) | Raloksifenin solunum yolu ile veya burundan uygulanması. | |
| DK0759747T3 (da) | Transdermal indretning til administration gennem de-epitheliseret hud | |
| YU59092A (sh) | Formulacije aerosola koji ne sadrže hlorofluorougljenična jedinjenja | |
| ATE340581T1 (de) | Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe | |
| DE69620877D1 (de) | Arzneimittelformulierungen für il-12 | |
| ATE321529T1 (de) | Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung | |
| DE69929313D1 (de) | Verfahren und zusammensetzungen zur verabreichung von taxanen | |
| ATE329608T1 (de) | Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung | |
| CL2004001642A1 (es) | Uso de un hidrolizado de proteina de pescado util para elaborar composiciones farmaceuticas y nutricionales, metodo de elaboracion de dicho hidrolizado. | |
| HUP0301349A2 (hu) | IL-11-tartalmú készítmények | |
| ATE198050T1 (de) | Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia | |
| ATE202931T1 (de) | Taxanderivate enthaltende arzneizubereitungen | |
| CY1114734T1 (el) | Φαρμακευτικες συνθεσεις και μεθοδοι χρησιμες για ρυθμιση αγγειογενεσης | |
| NO20023464D0 (no) | Sammensetning for intestinal avlevering | |
| NO980296L (no) | Forbedrede terapeutiske midler | |
| SE0001916D0 (sv) | Novel formulation | |
| DK1165102T3 (da) | Matrixproteinpræparater til podning i ikke-mineraliseret væv | |
| ATE301453T1 (de) | Injizierbare arzneiformulierungen von partricin derivaten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |